nervous system; Ex(9-39), exendin(9-39); FFA, free fatty acid; FFA2, free fatty acid receptor 2 (formerly known as GPR43); FFA2−/−, FFA2 knockout mice; FFA3, free fatty acid receptor 3 (formerly GPR41); FFA3−/−, FFA3 knockout mice; GI, gastrointestinal; GLP-1, glucagon-like peptide 1; GPCR, G protein-coupled receptor; 
| INTRODUC TI ON
The beneficial effects of dietary fiber are partially due to its microbial metabolism into the short-chain fatty acids (SCFAs) such as acetate and butyrate, with propionate accounting for ~25% of these fermentation products. 1 Intracolonic infusion of propionate stimulates the corelease of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in rodents 2, 3 and man, 4 promoting energy metabolism, 5 and preventing weight gain in overweight subjects. 6 SCFAs also exhibit a range of gastrointestinal (GI) activities that include epithelial barrier maintenance, 7 altered motility, [8] [9] [10] [11] and epithelial ion transport [12] [13] [14] that involve PYY and GLP-1, 15, 16 while butyrate is additionally (and uniquely among SCFAs) an energy source for enterocytes. SCFAs activate several G protein-coupled receptors (GPCRs) whose functional significance remains obscure primarily because of a lack of selective ligands.
GI mucosal signaling is further complicated by the presence of SCFA transporters that readily absorb these anions. 14 Nevertheless, studies utilizing selective antagonists and agonists have enabled some resolution of two GPCRs, namely free fatty acid 2 (FFA2; formerly GPR43) and FFA3 (GPR41). [15] [16] [17] In GI mucosae, FFA2 and FFA3 responses appear to be Gα q linked in L cells 15, 16 while Gα i/o coupling mediates FFA2-induced ghrelin secretion. 18 Propionate exhibits a similar affinity for FFA2 and FFA3 (as does acetate), but butyrate preferentially binds FFA3 and another receptor, GPR109A (also known as HCA2). 19 Notably, FFA2 and FFA3 GI expression patterns differ. In the distal small intestine and colon, FFA2 is expressed predominantly by L cells (that contain PYY and GLP-1), submucosal leukocytes, and mast cells, 16, 20 while FFA3 is expressed in L cells and enteric neurons in both myenteric and submucosal ganglia. 16 Selective FFA2 or FFA3 ligands have become commercially available [21] [22] [23] and revealed discrete functions for FFA2 15, 16, 24 and FFA3. 16, 25 Using a selective FFA2 agonist (named Compound 1), we showed that FFA2 agonism induced PYY, rather than GLP-1 activity in mouse colonic mucosa, activating anorexigenic pathways without improving glucose tolerance in vivo in lean or obese mice. 24 The majority of L cell vesicles contain one or the other peptide; 26 thus, independent release is possible but has not been a common observation to date. In fact, this selective FFA2 agonist suppressed insulin levels in vivo, so we concluded that FFA2 could be a therapeutic target for obesity rather than type 2 diabetes. 24 In contrast, FFA3 signaling appears to be primarily neural 16, 27 and in the GI tract may involve cholinergic nicotinic (in the rat ascending colon 17 ) and 5-hydroxytryptamine (5-HT) mechanisms 27 and possibly vasoactive intestinal polypeptide (VIP 16 ), although FFA3 expression has also been observed in human colon epithelia. 28 Species variations in the signaling bias of FFA2 and FFA3
agonists have presented significant challenges for their translation. 23 Mindful of this challenge and the availability of selective agonists, our primary aim was to test the hypothesis that FFA3
signaling was predominantly neuronal, while FFA2 signaling was not neuronally mediated, and propionate was a coagonist at FFA2
and FFA3. The FFA3 antagonist, AR399519 (alongside the FFA3 agonist, AR420626 18 ) was used to assess the involvement of FFA3 in propionate responses. Additionally, the regional sensitivity to AR420626 was established in mouse GI tract and, importantly, in human colonic mucosa and the endogenous mediators of FFA3 mucosal signaling were compared with FFA2 enteroendocrine signaling in mouse mucosae. and FFA3 agonism and propionate responses in gastrointestinal mucosae.
• FFA3 signaling involved enteric neurons and was glucose independent, whereas FFA2 signaling involved PYY and was mucosal derived. Luminal propionate costimulated FFA2 and FFA3 signaling and slowed colonic transit.
• SCFAs coactivate enteric mucosal hormone and neural pathways to modulate gut functions. followed by 100 n mol L −1 PYY (basolateral) were added to human colon mucosal preparations. In the rare event that a pellet was excreted during drug incubation periods, then that pellet's movement was excluded from the pooled data.
| Methods

| Mucosal ion transport (short-circuit current; I sc ) in vitro
| Endogenous fecal pellet propulsion measurement in mouse colon in vitro
| Data analysis
All data are presented as means ± 1SEM. Analyses were performed using GraphPad Prism v7.03, by Student's t test or one-way ANOVA with Dunnett's or Bonferroni's multiple comparison post hoc tests, as appropriate. When comparing the effect of a pretreatment or the presence/absence of glucose in an adjacent mucosal preparation, the control and experimental agonist responses were compared using Student's t test. When more than one pretreatment was compared (eg, after different antagonists but using the same agonist), then one-way ANOVA with Dunnett's posttest was applied. P ≤ 0.05 was statistically significant.
| RE SULTS
| Mucosal FFA3 agonism involves submucosal neurons, not PYY mechanisms as observed for FFA2 agonism
FFA3 activity was monitored using the selective agonist, AR420626.
When added apically (after VIP), AR420626 elicited monophasic reductions in Isc ( Figure 1A ) in mucosal preparations from the small and large intestine ( Figure 1B ). The greatest FFA3 efficacy was observed in distal regions (terminal ileum, ascending, and descending colon) in contrast with more uniform FFA2 signaling (using the commercially available agonist, PA; 100 n mol L −1 apically, Supporting information Figure S1A , B). In the descending colon, apical AR420626 responses were concentration dependent, exhibiting an EC 50 value of 22.6 n mol L −1 (11.3-45 Values are the mean ± 1SEM from 3-7 observations and statistical differences between control and experimental groups are as shown (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001) and not neuronal in the same colonic regions. TTX alone reduced basal Isc levels (data not shown) indicating the presence of a neurogenic secretory tone, as observed previously in mouse and human colon. 29, 33 Previous studies have revealed that FFA2-induced GLP-1 and PYY release from murine L cells was glucose dependent. 15, 24 In contrast, we found that FFA3 responses were insensitive to glucose substitution with mannitol on either mucosal surface ( Figure 1E ).
Predictably, the internal control, phloridzin was only effective when apical glucose was present, representing the blockade of this absorptive Na + -linked mechanism ( Figure 1E) . Notably, AR420626 mucosal responses in human colon mucosa were also monophasic reductions in Isc and this activity was TTX sensitive, and Y1/Y2 independent ( Figure 1F ), demonstrating conserved FFA3 mechanisms in human and mouse colonic mucosae.
FFA3 agonism has been shown to inhibit cholinergic neurotransmission in rat colon mucosa 17 while in mouse small intestine, FFA3 is colocalized with VIP in neurons located within both the submucosal and myenteric plexi. 16 We set out to ascertain which neurotransmitters predominantly mediate FFA3 responses but could not pursue VIP-specific mechanisms, as in our hands, or hexamethonium, in both colonic regions (data not included).
| FFA3 antagonism reveals tonic FFA3 activity in mouse and human colonic mucosa
Competitive FFA3 antagonism with AR399519 (applied apically) re- The removal of apical glucose significantly reduced the 1˚ propionate's response in ascending colon and it also significantly inhibited the PYY-mediated 2˚ component in both colonic regions ( Figure 4F ).
This glucose sensitivity is most likely FFA2 mediated, that is, L cell derived, since selective FFA2 agonism in mucosal preparations (with PA or Cpd1 24 ) is entirely glucose dependent. In contrast, propionate's 1˚ response in the descending colon was glucose independent, and notably, this component was not GLP-1 mediated.
| FFA3 antagonism inhibits propionate responses in mouse colon mucosae
FFA3 antagonism with AR399519 revealed a difference in FFA3 tonic activity in the mouse ascending versus the descending colon ( Figure 3A) . In further support of this observation, the presence of AR399519 virtually abolished the 1˚ responses to propionate in the ascending colon ( Figure 5A ) but had no effect on the smaller 1˚ response in the descending colon ( Figure 5B ). The 1˚ component of propionate's response is predominantly neuronal (Figure 4D ), so we infer that FFA3 is most likely to be present on submucosal secretory 
| FFA2 and FFA3 agonists slow fecal pellet propulsion in vitro
In vitro studies have shown previously that L cell-derived PYY mediates free fatty acid receptor FFA1 and FFA4 activation in mucosal preparations and that selective FFA1 and FFA4 agonists also slow colonic transit in vitro and in vivo. 37 Having uncovered divergent However, the cellular mechanisms of FFA2 and FFA3 selective signaling and their glucose dependence differed markedly, as hypothesized. FFA2 agonism involved L cell-derived PYY and this mechanism was glucose dependent 24 and enteric neuron independent, while FFA3 signaling was glucose independent and involved submucosal cholinergic neurotransmission (nicotinic, predominantly)
in combination with CGRP ( Figure 8) . Notably, the neural FFA3 Previously we established that selective FFA2 agonism involved endogenous PYY antisecretory and antimotility responses, alongside a suppression of food intake that lead to a reduction in body weight in WT mice, and these activities were absent in FFA2−/− mice or their tissues. 24 We were unable to detect significant GLP-1 involvement using this first-in-class FFA2 agonist; a finding that was corroborated using the commercially available FFA2 agonist, PA in the present study. However, GLP-1 release occurs with FFA2 agonists or SCFA administration to colonic crypt cultures and this is a glucose-dependent mechanism. 3, 15, 16, 40 In native mucosal preparations, secreted GLP-1 is probably inactivated rapidly 24 than peptide copackaging as indicated by early ultrastructural studies. 41 Hence, preferential FFA2-PYY signaling could be functionally significant, and its amplification by SCFA-enhanced PYY transcription also holds therapeutic potential. 42 The neural FFA3 activity that we observed here in mouse and human colon also differs markedly from FFA1 and FFA4 agonism, 37 GPR119 activity 43, 44 as well as other L cell sensing mechanisms that all involve endogenous PYY and/or GLP-1 and require glucose. 45, 46 In addition to its neural expression, FFA3 is to some extent expressed by L cells, for example, in mouse proximal colon, 47 and the same FFA3 agonist that we used (AR420626, but at ≥100x the concentration) stimulated GLP-1 release from colonic crypt preparations, although with much lower efficacy than propionate. 16 Taken together, it appears that neither PYY nor GLP-1 is involved in acute FFA3 activity in mouse or human colonic mucosa and that neural FFA3 pathways predominate over ( Figure 8 ). Previously, we found that all cholinergic submucous plexus neurons contain CGRP (in the distal colon 34 (Supporting information Data S1). In the present study, we confirmed that this 2˚ aspect was solely PYY mediated as it was abolished by a combination of Y1 and Y2 antagonists in ascending and descending colon mucosae. L cell FFA2, therefore, contributes to the acute propionate response ( Figure 8 ) and this specific activity was glucose sensitive, in agreement with our previous study investigating PYY-mediated mechanisms, 24 and the increased PYY and GLP-1 release observed in vivo to a number of luminal stimuli including propionate. 48 Additionally, in the ascending colon, the GLP- response is likely to be a combination of FFA2 and FFA3 agonism.
In the descending colon, the small 1˚ increase in Isc to propionate was significantly inhibited by TTX ( Figure 4D GLP-1 levels, reducing energy intake and longer term weight gain in overweight adults, 6 and promoting energy metabolism. 5 Based on these findings, we suggest that targeting FFA2 and FFA3 together may offer additional therapeutic potential for the treatment of obesity and type 2 diabetes.
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